Skip to main
TYRA

Tyra Biosciences (TYRA) Stock Forecast & Price Target

Tyra Biosciences (TYRA) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Tyra Biosciences is a promising investment with its clinical-stage biotechnology platform, SNAP, and its focus on precision medicines for oncology and genetically defined conditions. The potential for success in their product pipeline, particularly dabogratinib for non-muscle invasive bladder cancer, is high due to promising results and high unmet need in the market. Additionally, the company's target price of $54 per share and lack of competition in this specific market make it a strong investment opportunity.

Bears say

Tyra Biosciences is a biotechnology company with a negative outlook due to concerns about its drug candidate, dabogratinib, and its potential for limited efficacy and safety issues. While the company's precision medicine platform and drug candidates show promise, there are risks associated with launching a new drug and competition in the market. Additionally, there are concerns about the potential recurrence rates in patients with the targeted conditions and the limitations of current treatments. The company's recent data on dabogratinib also raises some red flags, and there are doubts about its ability to effectively compete with other approved drugs.

Tyra Biosciences (TYRA) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tyra Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tyra Biosciences (TYRA) Forecast

Analysts have given Tyra Biosciences (TYRA) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Tyra Biosciences (TYRA) has a Strong Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $49.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $49.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tyra Biosciences (TYRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.